Evidence map›Paper›PMID 40266525›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2025

The Production and Characterization of Synthetic Glycoconjugate Vaccines.

Aina Valenti, Peter H Seeberger, Oren Moscovitz

Abstract read
PubMed Publisher
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Aina ValentiMax Planck Institute of Colloids and Interfaces, Potsdam, Germany.
Peter H SeebergerMax Planck Institute of Colloids and Interfaces, Potsdam, Germany.
Oren MoscovitzMax Planck Institute of Colloids and Interfaces, Potsdam, Germany. Oren.Moscovitz@mpikg.mpg.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chemical conjugation of polysaccharides to protein carriers has become essential in carbohydrate vaccine development to enhance the poor immunogenicity of glycans. Neutral and uncharged carbohydrates induce T-cell independent responses, failing to produce robust IgG antibodies or sustained T-cell memory and conjugating native or synthetic glycans with carrier proteins such as the Cross-Reactive-Material-197 (CRM197) diphtheria toxin mutant, tetanus toxoid, or protein D of H. influenzae eliciting T-cell-dependent immune responses and class switching that produces high-affinity antibodies. This chapter describes the most commonly used synthetic glycoconjugates preparation strategy involving a spacer and a linker carrying a functional group, mostly amine, that couples the synthetic glycan to the carrier protein through its primary amine side chains of lysine residues and N-terminus. Our detailed protocol aims to advance the development of carbohydrate-binding antibodies that target tumor-associated carbohydrate antigens and expand our toolbox in the war against cancer.

Indexed as

GlycoconjugatesVaccines, ConjugateVaccines, SyntheticAnimalsAntigens, Tumor-Associated, CarbohydrateHumansAntigens, Tumor-Associated, CarbohydrateGlycoconjugatesVaccines, ConjugateVaccines, SyntheticAmine linkerCarbohydrate vaccinesCarrier proteinsGlycoconjugatesSynthetic glycansTumor-associated carbohydrate antigensVaccines

Identifiers

PMID40266525

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.